Skip to main content
Premium Trial:

Request an Annual Quote

GSK Licenses Lexicon s Gene Targeting Technologies

NEW YORK, Aug 15 - GlaxoSmithKline has agreed to a multi-year, non-exclusive sublicense to Lexicon Genetic’s gene targeting technologies, Lexicon said Wednesday.

The deal brings the total number of licensees for the technologies to 15.

Under the terms of the agreement, GlaxoSmithKline will pay a one-time fee of an undisclosed amount.

Lexicon Genetics of The Woodlands, Texas, uses gene knockout technology to identify genes of medical interest. In addition to licensing the technology, the company is also using it to develop its own drug discovery efforts.

Lexicon also sells subscriptions to its LexVision database of mouse gene-knockout data, which includes physiological data such as measurements of whole blood-cell count, X-rays, MRI and CT scans, and certain neurological tests. 

Last week, Lexicon announced that Bristol-Myers Squibb had chosen certain drug targets from LexVision to move into drug development. The announcement marked the first time one of Lexicon’s database subscribers had identified particularly promising drug targets.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.